Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue	$ 25,000	$ 126,000	$ 119,000	$ 332,000
Costs and expenses:
Cost of revenue	16,000	246,000	191,000	486,000
Research and development	7,304,000	5,512,000	14,716,000	9,966,000
General and administrative	1,563,000	925,000	3,210,000	2,146,000
Total costs and expenses	8,883,000	6,683,000	18,117,000	12,598,000
Loss from operations	(8,858,000)	(6,557,000)	(17,998,000)	(12,266,000)
Change in fair value of derivative liabilities		30,000		338,000
Interest expense		(81,000)		(348,000)
Loss on extinguishment of related party convertible promissory note				(2,180,000)
Other income (expense), net	30,000		103,000	(14,000)
Loss before provision for income taxes	(8,828,000)	(6,608,000)	(17,895,000)	(14,470,000)
Provision for income taxes	0	0	0	0
Net loss	(8,828,000)	(6,608,000)	(17,895,000)	(14,470,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Vaccinex, Inc.	(8,828,000)	(6,608,000)	(17,895,000)	(14,470,000)
Cumulative dividends on redeemable preferred stock		(800,000)		(1,592,000)
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (8,828,000)	$ (7,408,000)	$ (17,895,000)	$ (16,062,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.77)	$ (6.72)	$ (1.56)	$ (14.56)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	11,479,294	1,103,144	11,477,521	1,102,853